Zentalis Pharmaceuticalsllc Stock Short Ratio
| ZNTL Stock | USD 11.71 0.01 0.09% |
Zentalis PharmaceuticalsLlc fundamentals help investors to digest information that contributes to Zentalis PharmaceuticalsL's financial success or failures. It also enables traders to predict the movement of Zentalis Stock. The fundamental analysis module provides a way to measure Zentalis PharmaceuticalsL's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zentalis PharmaceuticalsL stock.
Zentalis | Short Ratio |
Zentalis PharmaceuticalsLlc Company Short Ratio Analysis
Zentalis PharmaceuticalsL's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Zentalis PharmaceuticalsL Short Ratio | 22.49 X |
Most of Zentalis PharmaceuticalsL's fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zentalis PharmaceuticalsLlc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Zentalis Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Zentalis PharmaceuticalsL is extremely important. It helps to project a fair market value of Zentalis Stock properly, considering its historical fundamentals such as Short Ratio. Since Zentalis PharmaceuticalsL's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Zentalis PharmaceuticalsL's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Zentalis PharmaceuticalsL's interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Zentalis PharmaceuticalsLlc has a Short Ratio of 22.49 times. This is much higher than that of the Biotechnology sector and 203.51% higher than that of the Health Care industry. The short ratio for all United States stocks is notably lower than that of the firm.
Zentalis PharmaceuticalsL Institutional Holders
Institutional Holdings refers to the ownership stake in Zentalis PharmaceuticalsL that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Zentalis PharmaceuticalsL's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Zentalis PharmaceuticalsL's value.| Shares | Decheng Capital Llc | 2023-12-31 | 2.1 M | Woodline Partners Lp | 2023-12-31 | 1.4 M | Geode Capital Management, Llc | 2023-12-31 | 1.3 M | Primecap Management Company | 2023-12-31 | 1 M | Tybourne Capital Management (hk) Ltd | 2023-12-31 | 961.5 K | Dimensional Fund Advisors, Inc. | 2023-12-31 | 724 K | Bank Of America Corp | 2023-12-31 | 718.6 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 609.5 K | Goldman Sachs Group Inc | 2023-12-31 | 585.8 K | Matrix Capital Management Company, Llc | 2023-12-31 | 14 M | Eventide Asset Management, Llc | 2023-12-31 | 11.6 M |
Zentalis Fundamentals
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 393.9 M | ||||
| Shares Outstanding | 71.01 M | ||||
| Shares Owned By Insiders | 4.26 % | ||||
| Shares Owned By Institutions | 95.74 % | ||||
| Number Of Shares Shorted | 16.64 M | ||||
| Price To Book | 2.18 X | ||||
| EBITDA | (252.55 M) | ||||
| Net Income | (292.19 M) | ||||
| Cash And Equivalents | 455.22 M | ||||
| Cash Per Share | 7.99 X | ||||
| Total Debt | 45.77 M | ||||
| Debt To Equity | 0.1 % | ||||
| Current Ratio | 9.61 X | ||||
| Book Value Per Share | 6.18 X | ||||
| Cash Flow From Operations | (207.82 M) | ||||
| Short Ratio | 22.49 X | ||||
| Earnings Per Share | (4.47) X | ||||
| Target Price | 34.4 | ||||
| Number Of Employees | 124 | ||||
| Beta | 1.73 | ||||
| Market Capitalization | 831.56 M | ||||
| Total Asset | 562.03 M | ||||
| Retained Earnings | (888.56 M) | ||||
| Working Capital | 427.35 M | ||||
| Net Asset | 562.03 M |
About Zentalis PharmaceuticalsL Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zentalis PharmaceuticalsLlc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zentalis PharmaceuticalsL using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zentalis PharmaceuticalsLlc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zentalis PharmaceuticalsL is a strong investment it is important to analyze Zentalis PharmaceuticalsL's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis PharmaceuticalsL's future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports:Check out Zentalis PharmaceuticalsL Piotroski F Score and Zentalis PharmaceuticalsL Altman Z Score analysis. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Zentalis Stock analysis
When running Zentalis PharmaceuticalsL's price analysis, check to measure Zentalis PharmaceuticalsL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zentalis PharmaceuticalsL is operating at the current time. Most of Zentalis PharmaceuticalsL's value examination focuses on studying past and present price action to predict the probability of Zentalis PharmaceuticalsL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zentalis PharmaceuticalsL's price. Additionally, you may evaluate how the addition of Zentalis PharmaceuticalsL to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is Zentalis PharmaceuticalsL's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis PharmaceuticalsL. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis PharmaceuticalsL listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.47) | Return On Assets (0.29) | Return On Equity (0.67) |
The market value of Zentalis PharmaceuticalsL is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis PharmaceuticalsL's value that differs from its market value or its book value, called intrinsic value, which is Zentalis PharmaceuticalsL's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis PharmaceuticalsL's market value can be influenced by many factors that don't directly affect Zentalis PharmaceuticalsL's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis PharmaceuticalsL's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis PharmaceuticalsL is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis PharmaceuticalsL's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.